von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects: The Hoorn Study
Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investig...
Saved in:
Published in | Arteriosclerosis, thrombosis, and vascular biology Vol. 19; no. 12; p. 3071 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Heart Association, Inc
01.12.1999
Hagerstown, MD Lippincott |
Subjects | |
Online Access | Get full text |
ISSN | 1079-5642 1524-4636 |
DOI | 10.1161/01.ATV.19.12.3071 |
Cover
Loading…
Abstract | Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance–stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways. |
---|---|
AbstractList | Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance–stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways. Abstract —Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance–stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways. Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance-stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways.Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether vWf and CRP predict mortality in a general population and whether vWf and CRP predict mortality through similar pathways. This study investigated the association of vWf and CRP with cardiovascular and all-cause mortality among diabetic and nondiabetic subjects. An age-, sex-, and glucose tolerance-stratified sample (n=631) of a population-based cohort aged 50 to 75 years was followed prospectively for 5 years. After 5 years of follow-up, 58 subjects had died (24 of cardiovascular causes). vWf (>1.56 IU/mL) and CRP (>2.84 mg/L) levels in the upper tertile were associated with, respectively, a 3- and 2-fold increase in cardiovascular mortality after adjustment for age, sex, and glucose tolerance status. Analyses in nondiabetic and diabetic subjects separately gave similar results. After further adjustment for hypertension, levels of HDL cholesterol and triglyceride, smoking habits, ischemic heart disease, and peripheral arterial disease, the relative risks (RRs) were 3.0 (95% CI 1.2 to 7.9) for vWf and 1.4 (95% CI 0.6 to 3.5) for CRP. When both vWf and CRP were included in the latter multivariate analysis, the RRs were 3.0 (95% CI 1.1 to 7.9) for vWf and 1.3 (95% CI 0.5 to 3.4) for CRP. The association between vWf and risk of cardiovascular mortality was independent of blood group (O versus non-O) and, moreover, similar among subjects with different blood groups. Repeating the analyses for all-cause mortality gave similar results for CRP. For vWf, the RR was 2.0 (95% CI 1.1 to 3.5) after adjustment for all other risk factors. Increased levels of vWf are independently associated with cardiovascular and all-cause mortality in both diabetic and nondiabetic subjects. The association between increased levels of CRP and cardiovascular mortality was partly explained by other risk factors. Mutual adjustment of vWf and CRP did not markedly change the results, favoring the hypothesis that vWf and CRP predict mortality through different pathways. |
Author | Jager, Agnes Dekker, Jacqueline M. Kostense, Piet J. Nijpels, Giel van Hinsbergh, Victor W. M. Bouter, Lex M. Emeis, Jef J. Yudkin, John S. Heine, Robert J. Stehouwer, Coen D. A. |
AuthorAffiliation | From the Institute for Research in Extramural Medicine (A.J., P.J.K., G.N., J.M.D., R.J.H., L.M.B., C.D.A.S.), the Institute for Cardiovascular Research (V.W.M.v.H., C.D.A.S.), and the Department of Epidemiology and Biostatistics (P.J.K., L.M.B.), Vrije Universiteit, Amsterdam, Netherlands; Gaubius Laboratory (V.W.M.v.H., J.J.E.), TNO Prevention and Health, Leiden, the Netherlands; the Centre for Diabetes and Cardiovascular Risk (J.S.Y.), Department of Medicine, University College London Medical School, London, UK; and the Department of Internal Medicine (R.J.H., C.D.A.S.), University Hospital Vrije Universiteit, Amsterdam, the Netherlands |
AuthorAffiliation_xml | – name: From the Institute for Research in Extramural Medicine (A.J., P.J.K., G.N., J.M.D., R.J.H., L.M.B., C.D.A.S.), the Institute for Cardiovascular Research (V.W.M.v.H., C.D.A.S.), and the Department of Epidemiology and Biostatistics (P.J.K., L.M.B.), Vrije Universiteit, Amsterdam, Netherlands; Gaubius Laboratory (V.W.M.v.H., J.J.E.), TNO Prevention and Health, Leiden, the Netherlands; the Centre for Diabetes and Cardiovascular Risk (J.S.Y.), Department of Medicine, University College London Medical School, London, UK; and the Department of Internal Medicine (R.J.H., C.D.A.S.), University Hospital Vrije Universiteit, Amsterdam, the Netherlands |
Author_xml | – sequence: 1 givenname: Agnes surname: Jager fullname: Jager, Agnes organization: From the Institute for Research in Extramural Medicine (A.J., P.J.K., G.N., J.M.D., R.J.H., L.M.B., C.D.A.S.), the Institute for Cardiovascular Research (V.W.M.v.H., C.D.A.S.), and the Department of Epidemiology and Biostatistics (P.J.K., L.M.B.), Vrije Universiteit, Amsterdam, Netherlands; Gaubius Laboratory (V.W.M.v.H., J.J.E.), TNO Prevention and Health, Leiden, the Netherlands; the Centre for Diabetes and Cardiovascular Risk (J.S.Y.), Department of Medicine, University College London Medical School, London, UK; and the Department of Internal Medicine (R.J.H., C.D.A.S.), University Hospital Vrije Universiteit, Amsterdam, the Netherlands – sequence: 2 givenname: Victor surname: van Hinsbergh middlename: W. M. fullname: van Hinsbergh, Victor W. M. – sequence: 3 givenname: Piet surname: Kostense middlename: J. fullname: Kostense, Piet J. – sequence: 4 givenname: Jef surname: Emeis middlename: J. fullname: Emeis, Jef J. – sequence: 5 givenname: John surname: Yudkin middlename: S. fullname: Yudkin, John S. – sequence: 6 givenname: Giel surname: Nijpels fullname: Nijpels, Giel – sequence: 7 givenname: Jacqueline surname: Dekker middlename: M. fullname: Dekker, Jacqueline M. – sequence: 8 givenname: Robert surname: Heine middlename: J. fullname: Heine, Robert J. – sequence: 9 givenname: Lex surname: Bouter middlename: M. fullname: Bouter, Lex M. – sequence: 10 givenname: Coen surname: Stehouwer middlename: D. A. fullname: Stehouwer, Coen D. A. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1210292$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10591689$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kl1rFDEUhgep2A_9Ad7IIOJVZ81JMpmNd2W1Vqgf2FXxKmQyZ9ms2aQmmZb992bdLYWCFyHnkOc9HN43x9WBDx6r6jmQCYCANwQmZ_MfE5AToBNGOnhUHUFLecMFEwelJp1sWsHpYXWc0ooQwiklT6pDIK0EMZVH1XgTfP3TOod91H6oz7XJIZ7Ws-YbltLeYP01hozWn9bb97b5hTrWn0LM2tm8qa2v31ndY7bmH_A5-OGuvxr7FZqc3tbzJdYXIURfX-Vx2DytHi-0S_hsf59U38_fz2cXzeWXDx9nZ5eN4azlDSw4MOQEQNOhbcvuQ0cG3XLWa64lkXxAMRUL3qOhgzBM4FR2AkyPVEgY2En1ejf3OoY_I6as1jYZdE57DGNSQjIuBYgCvnwArsIYfdlN0WKaZN10C73YQ2O_xkFdR7vWcaPu3CzAqz2gk9FuURw1Nt1zFAiVtGDdDjMxpBRxoYzNOtvgc9TWlXlqG68ioEq8CmRRqm28RQkPlPc7_F_Dd5rb4DLG9NuNtxjVErXLS7X9E0yQtgEpJdDSNuUwzv4CyGu0kA |
CODEN | ATVBFA |
CitedBy_id | crossref_primary_10_3389_fcvm_2022_976817 crossref_primary_10_1046_j_1365_2796_2000_00754_x crossref_primary_10_1016_j_diabres_2004_05_009 crossref_primary_10_18214_jkaem_2009_11_1_7 crossref_primary_10_3346_jkms_2008_23_1_77 crossref_primary_10_1016_S0021_9150_03_00050_9 crossref_primary_10_1093_ndt_gfh680 crossref_primary_10_1016_S0002_9149_02_02556_0 crossref_primary_10_5694_mja2_50239 crossref_primary_10_1046_j_1365_2796_2003_01156_x crossref_primary_10_1182_blood_2004_01_0107 crossref_primary_10_1371_journal_pmed_1000099 crossref_primary_10_1155_2017_5620314 crossref_primary_10_1046_j_0954_6820_2003_01246_x crossref_primary_10_1007_s12185_012_1041_x crossref_primary_10_1161_ATVBAHA_113_301359 crossref_primary_10_1016_j_cca_2007_03_007 crossref_primary_10_1016_S0021_9150_02_00371_4 crossref_primary_10_1111_vox_12786 crossref_primary_10_1016_j_ejim_2008_07_008 crossref_primary_10_3132_dvdr_2007_007 crossref_primary_10_2337_diabetes_53_6_1570 crossref_primary_10_1373_clinchem_2007_100271 crossref_primary_10_1373_clinchem_2008_115923 crossref_primary_10_1097_00041433_200010000_00010 crossref_primary_10_1016_j_thromres_2008_02_003 crossref_primary_10_1111_j_1538_7836_2005_01369_x crossref_primary_10_1111_j_1365_2796_2007_01770_x crossref_primary_10_1111_j_1538_7836_2004_00965_x crossref_primary_10_1111_j_1365_2796_2008_02015_x crossref_primary_10_1016_j_cca_2005_12_030 crossref_primary_10_2337_db06_0116 crossref_primary_10_1186_1758_5996_6_32 crossref_primary_10_2337_dc06_1747 crossref_primary_10_1016_S1575_0922_03_74506_9 crossref_primary_10_1016_j_cjca_2017_10_017 crossref_primary_10_2337_diacare_29_02_06_dc05_1700 crossref_primary_10_2337_diacare_25_8_1371 crossref_primary_10_1111_j_1365_2265_2011_04190_x crossref_primary_10_1210_jc_2008_2534 crossref_primary_10_3899_jrheum_090699 crossref_primary_10_1111_j_1399_5618_2009_00757_x crossref_primary_10_1097_MBC_0b013e3282f54522 crossref_primary_10_15407_internalmed2020_01_043 crossref_primary_10_1016_j_atherosclerosis_2004_01_002 crossref_primary_10_1097_01_hjh_0000217841_34595_59 crossref_primary_10_3389_fmed_2020_00543 crossref_primary_10_1016_j_cjca_2022_02_002 crossref_primary_10_1007_s10787_014_0212_1 crossref_primary_10_1016_j_atherosclerosis_2014_06_004 crossref_primary_10_1093_ije_dyv205 crossref_primary_10_1097_MD_0000000000001708 crossref_primary_10_1155_2012_481840 crossref_primary_10_1084_jem_20080130 crossref_primary_10_3945_jn_111_139733 crossref_primary_10_1002_alz_14272 crossref_primary_10_1016_j_ijcard_2011_06_088 crossref_primary_10_1046_j_1464_5491_2001_00416_x crossref_primary_10_1016_j_thromres_2010_01_031 crossref_primary_10_1093_ndt_16_10_2028 crossref_primary_10_3109_08958378_2011_593587 crossref_primary_10_1177_1076029607305115 crossref_primary_10_1289_ehp_7938 crossref_primary_10_1016_j_cca_2005_12_027 crossref_primary_10_2337_diabetes_52_2_442 crossref_primary_10_51248__v42i1_594 crossref_primary_10_1046_j_1467_789X_2002_00056_x crossref_primary_10_3945_jn_114_201236 crossref_primary_10_1016_j_atherosclerosis_2017_01_005 crossref_primary_10_1002_ajmg_b_30824 crossref_primary_10_1586_erc_09_184 crossref_primary_10_1056_NEJMoa032804 crossref_primary_10_1016_j_diabres_2014_04_006 crossref_primary_10_1373_49_4_669 crossref_primary_10_1007_s11033_014_3026_8 crossref_primary_10_1007_BF02913314 crossref_primary_10_1161_HYPERTENSIONAHA_111_174557 crossref_primary_10_1016_j_cca_2011_07_030 crossref_primary_10_1007_s11428_008_0252_5 crossref_primary_10_1016_S0002_9149_03_00657_X crossref_primary_10_1373_clinchem_2007_099465 crossref_primary_10_1053_j_seminhematol_2004_09_009 crossref_primary_10_1309_LM0XULJ3JAYARH9K crossref_primary_10_3923_pjbs_2005_1383_1386 crossref_primary_10_1111_dom_13136 crossref_primary_10_1007_BF03345357 crossref_primary_10_1080_10408360600966753 crossref_primary_10_1111_j_1538_7836_2006_01949_x crossref_primary_10_1507_endocrj_52_89 crossref_primary_10_3747_pdi_2012_00004 crossref_primary_10_1080_10641963_2021_1896729 crossref_primary_10_2337_ds18_0002 crossref_primary_10_3390_ijms21207804 crossref_primary_10_1093_eurheartj_ehi104 crossref_primary_10_1038_sj_jhh_1001812 crossref_primary_10_1515_jpem_2010_126 crossref_primary_10_1111_j_1538_7836_2005_01305_x crossref_primary_10_1002_clc_20681 crossref_primary_10_1111_j_1600_0609_2006_00656_x crossref_primary_10_1111_j_1538_7836_2005_01694_x crossref_primary_10_1111_j_1365_2796_2004_01350_x crossref_primary_10_1097_HJH_0b013e328350a487 crossref_primary_10_2337_diacare_26_7_2165 crossref_primary_10_1160_th14_05_0457 crossref_primary_10_1046_j_1365_2796_2002_01024_x crossref_primary_10_1007_s00125_015_3586_8 crossref_primary_10_1530_JME_13_0079 crossref_primary_10_1007_s00394_017_1420_4 crossref_primary_10_1097_MD_0000000000011269 crossref_primary_10_1007_s00441_008_0685_6 crossref_primary_10_1002_dmrr_2406 crossref_primary_10_1093_ndt_gfr735 crossref_primary_10_1007_BF02981972 crossref_primary_10_1016_j_amjmed_2005_06_057 crossref_primary_10_1093_ndt_16_3_529 crossref_primary_10_1093_ckj_sfz076 crossref_primary_10_1007_s11239_012_0682_1 crossref_primary_10_1053_j_seminhematol_2004_11_001 crossref_primary_10_1093_clinchem_48_10_1781 crossref_primary_10_1016_S1056_8727_02_00184_8 crossref_primary_10_1046_j_1464_5491_2002_00808_x crossref_primary_10_1093_ndt_16_7_1442 crossref_primary_10_1038_s41598_017_07029_7 crossref_primary_10_2217_bmm_11_108 crossref_primary_10_1111_j_1538_7836_2005_01279_x crossref_primary_10_1111_j_1464_5491_2004_01388_x crossref_primary_10_1038_ncpcardio1322 crossref_primary_10_1007_s00125_007_0905_8 crossref_primary_10_1007_s00421_020_04419_0 crossref_primary_10_1002_eji_201646386 crossref_primary_10_1016_j_jdiacomp_2019_107413 crossref_primary_10_1007_s11892_013_0380_1 crossref_primary_10_1007_s13410_016_0479_4 crossref_primary_10_1111_j_1747_4949_2010_00420_x crossref_primary_10_1097_00019501_200109000_00003 crossref_primary_10_1073_pnas_242407999 crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_108044 crossref_primary_10_1016_j_jacl_2013_04_004 crossref_primary_10_1016_S0021_9150_03_00198_9 crossref_primary_10_1007_s12603_020_1385_5 crossref_primary_10_1093_ndt_gfg080 crossref_primary_10_1590_S0004_27302008000200030 crossref_primary_10_1016_j_thromres_2011_07_033 crossref_primary_10_1161_JAHA_116_004554 crossref_primary_10_3389_fcvm_2022_1038030 crossref_primary_10_1111_j_1523_1755_2002_kid571_x crossref_primary_10_1111_j_1538_7836_2005_01571_x crossref_primary_10_1046_j_1365_2141_2003_04776_x crossref_primary_10_1186_s12916_014_0237_8 crossref_primary_10_1007_s11892_002_0052_z crossref_primary_10_1016_S0021_9150_01_00626_8 crossref_primary_10_1067_mhj_2002_124054 crossref_primary_10_2337_diacare_28_6_1383 crossref_primary_10_1016_j_mehy_2012_12_035 crossref_primary_10_1002_ptr_6707 crossref_primary_10_1016_j_diabres_2007_10_002 crossref_primary_10_1111_j_1462_8902_2004_00340_x crossref_primary_10_1097_00001573_200207000_00001 crossref_primary_10_1016_j_pcad_2004_02_003 crossref_primary_10_1111_j_1538_7836_2005_01763_x crossref_primary_10_1097_00004872_200209000_00017 crossref_primary_10_1146_annurev_med_53_082901_103904 crossref_primary_10_1016_S0021_9150_02_00316_7 crossref_primary_10_1093_rheumatology_ken206 crossref_primary_10_1186_s13098_017_0225_1 crossref_primary_10_1016_j_diabres_2007_01_025 crossref_primary_10_1007_s00125_005_1799_y crossref_primary_10_1007_s00277_006_0085_5 crossref_primary_10_1046_j_1365_2362_2002_01090_x crossref_primary_10_1042_CS20050025 crossref_primary_10_1161_CIRCULATIONAHA_115_017563 crossref_primary_10_1046_j_1365_2362_2002_00919_x crossref_primary_10_2337_diabetes_51_4_1157 crossref_primary_10_1016_S0002_9149_03_00504_6 crossref_primary_10_1016_S0735_1097_02_02565_2 crossref_primary_10_1200_JCO_2002_20_13_3042 crossref_primary_10_1016_j_jdiacomp_2006_10_004 crossref_primary_10_1016_S1537_1891_02_00295_1 crossref_primary_10_1016_j_cyto_2019_02_005 crossref_primary_10_2337_dc11_1588 crossref_primary_10_1016_j_atherosclerosis_2008_08_042 crossref_primary_10_1016_j_envres_2005_03_011 crossref_primary_10_1530_EJE_07_0470 crossref_primary_10_1111_joim_12128 crossref_primary_10_1016_j_atherosclerosis_2013_12_002 crossref_primary_10_1080_00365510152379058 crossref_primary_10_1097_MOL_0b013e32832ac03e crossref_primary_10_1007_s13410_015_0389_x crossref_primary_10_1007_s11560_022_00590_x crossref_primary_10_1186_1743_8977_6_25 crossref_primary_10_1586_eem_09_44 crossref_primary_10_1177_1358863X15622281 crossref_primary_10_1017_S0033291713002043 crossref_primary_10_1093_ndt_gfh015 crossref_primary_10_1007_s00125_004_1491_7 crossref_primary_10_1210_jc_2004_0616 crossref_primary_10_1016_j_metabol_2006_06_024 |
Cites_doi | 10.3109/00365518709168882 10.1093/clinchem/18.6.499 10.1056/NEJM199408183310709 10.1161/circ.98.21.2241 10.1161/atvb.17.11.3321 10.1055/s-0038-1656120 10.1056/NEJM199408183310701 10.1136/bmj.311.7017.1405 10.1161/circ.88.3.8353913 10.1161/atvb.17.6.1121 10.1136/hrt.55.1.58 10.1161/atv91.12.9.1525121 10.1056/NEJM198907203210301 10.1182/blood.V93.2.564 10.1161/atvb.18.2.323 10.1172/JCI119561 10.1056/NEJM199704033361401 10.1161/circ.94.9.2057 10.1136/bmj.311.7007.711 10.1016/S0008-6363(96)00272-6 10.1016/S0021-9150(97)00081-6 10.1161/atvb.17.10.2167 10.1016/S0140-6736(96)07591-5 10.2337/diabetes.47.6.859 10.1161/circ.98.4.294 10.1136/bmj.312.7038.1061 10.1093/oxfordjournals.aje.a008963 10.1016/0049-3848(89)90317-4 10.1161/circ.97.20.2007 10.1161/circ.98.8.731 10.1161/atvb.19.3.617 10.1007/s001250050612 10.1007/BF00274216 10.1007/s001250050822 10.1016/0049-3848(96)00021-7 10.1161/atvb.18.9.1359 10.1016/0140-6736(93)91288-W 10.1161/circ.89.3.8124825 10.1016/0024-3205(89)90613-9 10.1056/NEJM198512193132501 10.1016/0140-6736(92)91401-S 10.1007/BF02369357 10.1046/j.1365-2362.1997.2180766.x 10.1038/362801a0 10.1056/NEJM199503093321003 10.1111/j.1365-2141.1994.tb05079.x 10.1161/circ.96.4.1102 10.1007/BF00403180 10.1136/hrt.66.5.351 |
ContentType | Journal Article |
Copyright | 1999 American Heart Association, Inc. 2000 INIST-CNRS Copyright American Heart Association, Inc. Dec 1999 |
Copyright_xml | – notice: 1999 American Heart Association, Inc. – notice: 2000 INIST-CNRS – notice: Copyright American Heart Association, Inc. Dec 1999 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM K9. 7X8 |
DOI | 10.1161/01.ATV.19.12.3071 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4636 |
EndPage | 3071 |
ExternalDocumentID | 47772086 10591689 1210292 10_1161_01_ATV_19_12_3071 00043605-199912000-00034 |
Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GroupedDBID | --- .3C .55 .GJ .Z2 01R 0R~ 1J1 23N 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO ABASU ABBUW ABDIG ABJNI ABPXF ABQRW ABVCZ ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFS ACGOD ACILI ACLDA ACPRK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFFNX AFUWQ AGINI AHJKT AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC AYCSE BAWUL BOYCO BQLVK BS7 C1A C45 CS3 DIK DIWNM DUNZO E.X E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FRP FW0 GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B N~M O9- OAG OAH OB2 OCUKA ODA OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ PZZ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW V2I VVN W3M W8F WOQ WOW X3V X3W X7M XXN XYM YFH ZGI ZZMQN AAYXX ADGHP CITATION IQODW ADSXY CGR CUY CVF ECM EIF NPM K9. 7X8 |
ID | FETCH-LOGICAL-c4354-1f413e4011a2d55220d70da543ba4a9094de686f4bec2d6c36e89761cbe2691d3 |
ISSN | 1079-5642 |
IngestDate | Fri Jul 11 11:47:46 EDT 2025 Wed Aug 13 05:44:05 EDT 2025 Mon Aug 18 09:42:53 EDT 2025 Mon Jul 21 09:14:50 EDT 2025 Tue Jul 01 02:21:39 EDT 2025 Thu Apr 24 22:53:08 EDT 2025 Fri May 16 03:46:45 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Endocrinopathy Human Prognosis Diabetes mellitus Mortality Cardiovascular disease Thrombosis Vascular disease Follow up study Atherosclerosis Risk factor Willebrand factor C reactive protein |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4354-1f413e4011a2d55220d70da543ba4a9094de686f4bec2d6c36e89761cbe2691d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
PMID | 10591689 |
PQID | 204293786 |
PQPubID | 49288 |
PageCount | 1 |
ParticipantIDs | proquest_miscellaneous_69349616 proquest_journals_204293786 pubmed_primary_10591689 pascalfrancis_primary_1210292 crossref_citationtrail_10_1161_01_ATV_19_12_3071 crossref_primary_10_1161_01_ATV_19_12_3071 wolterskluwer_health_00043605-199912000-00034 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 1999-December |
PublicationDateYYYYMMDD | 1999-12-01 |
PublicationDate_xml | – month: 12 year: 1999 text: 1999-December |
PublicationDecade | 1990 |
PublicationPlace | Philadelphia, PA Hagerstown, MD |
PublicationPlace_xml | – name: Philadelphia, PA – name: Hagerstown, MD – name: United States – name: Hagerstown |
PublicationTitle | Arteriosclerosis, thrombosis, and vascular biology |
PublicationTitleAlternate | Arterioscler Thromb Vasc Biol |
PublicationYear | 1999 |
Publisher | American Heart Association, Inc Lippincott |
Publisher_xml | – name: American Heart Association, Inc – name: Lippincott |
References | e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 e_1_3_2_41_2 e_1_3_2_20_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_54_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_52_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_50_2 e_1_3_2_27_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_25_2 e_1_3_2_46_2 (e_1_3_2_48_2) 1990; 115 (e_1_3_2_43_2) 1999; 93 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_6_2 (e_1_3_2_1_2) 1988; 58 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_53_2 e_1_3_2_32_2 e_1_3_2_51_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 |
References_xml | – ident: e_1_3_2_30_2 doi: 10.3109/00365518709168882 – ident: e_1_3_2_32_2 doi: 10.1093/clinchem/18.6.499 – ident: e_1_3_2_3_2 doi: 10.1056/NEJM199408183310709 – ident: e_1_3_2_39_2 doi: 10.1161/circ.98.21.2241 – volume: 58 start-page: 249 year: 1988 ident: e_1_3_2_1_2 publication-title: Lab Invest – ident: e_1_3_2_13_2 doi: 10.1161/atvb.17.11.3321 – ident: e_1_3_2_7_2 doi: 10.1055/s-0038-1656120 – ident: e_1_3_2_14_2 doi: 10.1056/NEJM199408183310701 – ident: e_1_3_2_20_2 doi: 10.1136/bmj.311.7017.1405 – ident: e_1_3_2_28_2 doi: 10.1161/circ.88.3.8353913 – ident: e_1_3_2_16_2 doi: 10.1161/atvb.17.6.1121 – ident: e_1_3_2_53_2 doi: 10.1136/hrt.55.1.58 – ident: e_1_3_2_11_2 doi: 10.1161/atv91.12.9.1525121 – ident: e_1_3_2_54_2 doi: 10.1056/NEJM198907203210301 – ident: e_1_3_2_33_2 – volume: 93 start-page: 564 year: 1999 ident: e_1_3_2_43_2 publication-title: Blood doi: 10.1182/blood.V93.2.564 – ident: e_1_3_2_42_2 doi: 10.1161/atvb.18.2.323 – ident: e_1_3_2_46_2 doi: 10.1172/JCI119561 – ident: e_1_3_2_18_2 doi: 10.1056/NEJM199704033361401 – ident: e_1_3_2_41_2 doi: 10.1161/circ.94.9.2057 – ident: e_1_3_2_45_2 doi: 10.1136/bmj.311.7007.711 – ident: e_1_3_2_5_2 doi: 10.1016/S0008-6363(96)00272-6 – ident: e_1_3_2_10_2 doi: 10.1016/S0021-9150(97)00081-6 – ident: e_1_3_2_49_2 doi: 10.1161/atvb.17.10.2167 – ident: e_1_3_2_15_2 doi: 10.1016/S0140-6736(96)07591-5 – ident: e_1_3_2_52_2 doi: 10.2337/diabetes.47.6.859 – ident: e_1_3_2_44_2 doi: 10.1161/circ.98.4.294 – ident: e_1_3_2_51_2 doi: 10.1136/bmj.312.7038.1061 – ident: e_1_3_2_17_2 doi: 10.1093/oxfordjournals.aje.a008963 – ident: e_1_3_2_40_2 doi: 10.1016/0049-3848(89)90317-4 – ident: e_1_3_2_50_2 doi: 10.1161/circ.97.20.2007 – ident: e_1_3_2_19_2 doi: 10.1161/circ.98.8.731 – ident: e_1_3_2_26_2 doi: 10.1161/atvb.19.3.617 – ident: e_1_3_2_21_2 doi: 10.1007/s001250050612 – volume: 115 start-page: 339 year: 1990 ident: e_1_3_2_48_2 publication-title: J Lab Clin Med – ident: e_1_3_2_23_2 doi: 10.1007/BF00274216 – ident: e_1_3_2_29_2 – ident: e_1_3_2_22_2 doi: 10.1007/s001250050822 – ident: e_1_3_2_31_2 doi: 10.1016/0049-3848(96)00021-7 – ident: e_1_3_2_4_2 doi: 10.1161/atvb.18.9.1359 – ident: e_1_3_2_37_2 doi: 10.1016/0140-6736(93)91288-W – ident: e_1_3_2_34_2 doi: 10.1161/circ.89.3.8124825 – ident: e_1_3_2_47_2 doi: 10.1016/0024-3205(89)90613-9 – ident: e_1_3_2_38_2 doi: 10.1056/NEJM198512193132501 – ident: e_1_3_2_24_2 doi: 10.1016/0140-6736(92)91401-S – ident: e_1_3_2_27_2 – ident: e_1_3_2_25_2 doi: 10.1007/BF02369357 – ident: e_1_3_2_6_2 doi: 10.1046/j.1365-2362.1997.2180766.x – ident: e_1_3_2_2_2 doi: 10.1038/362801a0 – ident: e_1_3_2_8_2 doi: 10.1056/NEJM199503093321003 – ident: e_1_3_2_36_2 doi: 10.1111/j.1365-2141.1994.tb05079.x – ident: e_1_3_2_12_2 doi: 10.1161/circ.96.4.1102 – ident: e_1_3_2_35_2 doi: 10.1007/BF00403180 – ident: e_1_3_2_9_2 doi: 10.1136/hrt.66.5.351 |
SSID | ssj0004220 |
Score | 2.139917 |
Snippet | Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is uncertain whether... Abstract —Increased levels of von Willebrand factor (vWf) and C-reactive protein (CRP) predict cardiovascular mortality in selected populations. It is... |
SourceID | proquest pubmed pascalfrancis crossref wolterskluwer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 3071 |
SubjectTerms | Acute-Phase Reaction - metabolism Aged Atherosclerosis (general aspects, experimental research) Biological and medical sciences Blood and lymphatic vessels C-Reactive Protein - metabolism Cardiology. Vascular system Cohort Studies Coronary Disease - metabolism Coronary Disease - mortality Diabetes Mellitus, Type 2 - metabolism Diabetes Mellitus, Type 2 - mortality Female Follow-Up Studies Humans Male Medical sciences Middle Aged Prospective Studies Risk Factors Survival Analysis von Willebrand Factor - metabolism |
Title | von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects: The Hoorn Study |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-199912000-00034 https://www.ncbi.nlm.nih.gov/pubmed/10591689 https://www.proquest.com/docview/204293786 https://www.proquest.com/docview/69349616 |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBASQnxTxsAPPLGlxI7jxrxVaKjaNARSN-0tyocjVbRJtbQg-Ff4Z7mznTQZBQEvUeM4dpT79XI-3_2OkFdKhDmypnhKFtoTTAdeBGaGx2Xg5zJlQhuy6rMPcnouTi7Dy8HgRydqabNOR9n3nXkl_yNVaAO5YpbsP0i2HRQa4DfIF44gYTj-lYy_VCbqZYGbv2XuaucY16cHtqDRZIeGiMESBWCf0PuG1D1LY3WjBY7RsMb_6ohby6psz-tNim6augn-mFbVVWlCD3ubwRMMC51XNTwdfHMtaQGWX1imzRkO3Ma8Ot6nNnYHWTR6XlVMqZrOyxpDz4zX5-Kw9QSdYlJKaatBftzuaR0vtZ3pxLXlLrNPdYJCrO71x8oLpegrZ9UFIe-oWlBObPc3QDKT1zCazC5GTKG393pfeG2rpQEFmpdM2ipG14i3m0s3yE0OaxAsj3H6qUNFz7mlunBP7bbMYfY3v8yN1LRutJ79c2cFrz5ZFLaGyq5FDvT5WmHcRP3ZpE10jJ_ZPXLXrVroxELwPhno8gG5debiMh6SDSCRbpFILRKP6BaH1OHwiOJ1i0LaopDOS9qgznTooJA2KHxLAYPUYJAaDD4i5--PZ--mnivo4WVglQuPFWAyaVjRs4TnIVj-fj728yQUQZqIRPlK5FpGshCgWHgus0BqUBySZanmUrE8eEz2YH79lNBMZioLojyVPBFFpKNAJqoQQa7H40Il0ZD4zWuOM8d2j0VXFrFZ9UoW-ywGIcVMxYzHKKQhed3esrJUL3_qfNCT3fYO9KEoPiT7jSxjpzHqmKP1F4wjOSQv26ugznGPLil1taljqbCCA4MeTywAOo9iATQkXg8RsU2Yjs2mvkReYVzzNYwRgXj225H2ye3t__A52VtfbfQBmNjr9IWB-k9A5soL |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=von+Willebrand+factor%2C+C-reactive+protein%2C+and+5-year+mortality+in+diabetic+and+nondiabetic+subjects%3A+the+Hoorn+Study&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Jager%2C+A&rft.au=van+Hinsbergh%2C+V+W&rft.au=Kostense%2C+P+J&rft.au=Emeis%2C+J+J&rft.date=1999-12-01&rft.issn=1079-5642&rft.volume=19&rft.issue=12&rft.spage=3071&rft_id=info:doi/10.1161%2F01.ATV.19.12.3071&rft_id=info%3Apmid%2F10591689&rft.externalDocID=10591689 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon |